Phagocytosis of serum-opsonized zymosan down-regulates the expression of CR3 and FcRI in the membrane of human monocytes.
The effect of iC3b receptor (CR3)-mediated phagocytosis on the expression of CR (C3b receptor, CR3) and IgG FcR (FcRI, FcRII) has been investigated by using serum-opsonized zymosan as a multivalent ligand for CR3. Sixteen hours after a short (1-h) pretreatment of human monocyte monolayers with zymosan opsonized with human AB serum (250 micrograms/ml), CR3 expression (as assessed by flow cytometric analysis with mAb Mo1) was significantly reduced by 59 +/- 3% (mean +/- SEM, n = 15, p less than 0.001). Concomitant with CR3 down modulation, FcR binding activity (as assessed by binding of IgG-coated E) was also found to be decreased to 41 +/- 4% of control (n = 7, p less than 0.001). Reduced FcR function was paralleled by a decrease in the expression of FcRI (as assessed with mAb 32.2). This FcRI modulation was not caused by zymosan-bound IgG because zymosan opsonized with agammaglobulinemic serum equally down regulated CR3 and FcRI expression. Pretreatment with zymosan opsonized with human AB serum, however, did not change the expression of other IgG and C-binding sites such as FcRII (examined with mAb IV.3 and 2E1) and CR1 (assessed with mAb 57F) as well as of unrelated cell membrane structures (beta 2m, MHC class II). In contrast, co-modulation for FcR function and CR3 expression induced by polymeric IgG is accompanied by a decreased expression of FcRII. These data indicate that interaction of a specific receptor with its ligand not only changes the expression of the receptor triggered, but has also a modulating effect on other receptor systems on the same cell.
Wolf
H M
HM
Institute of Immunology, University of Vienna, Austria.
Mannhalter
J W
JW
Salzmann
H C
HC
Göttlicher
J
J
Ahmad
R
R
Eibl
M M
MM
D000943:Antigens, Differentiation / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D002450:Cell Communication; D002462:Cell Membrane / Q000378:metabolism; D003176:Complement C3 / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D016177:Macrophage-1 Antigen; D009000:Monocytes / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D009895:Opsonin Proteins; D010587:Phagocytosis; D011951:Receptors, Complement / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D011961:Receptors, Fc / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D017452:Receptors, IgG; D015054:Zymosan
D000943:Antigens, Differentiation; D003176:Complement C3; D007074:Immunoglobulin G; D016177:Macrophage-1 Antigen; D009895:Opsonin Proteins; D011951:Receptors, Complement; D011961:Receptors, Fc; D017452:Receptors, IgG; D015054:Zymosan